FGEP is a nonprofit organization working to eliminate barriers to access to HIV medications generated by intellectual property rights and other exclusive rights in Argentina.
Since 2006, Fundación Grupo Efecto Positivo (FGEP) has worked on antiretroviral (ARV) patents and, more recently, on access to direct-acting antivirals (DAAs). FGEP has a strong working relationship with Argentina’s patent office (INPI) and maintains effective collaborations with the government, civil society organizations (CSOs), and local generic manufacturers as leaders in the implementation of TRIPS flexibilities.
FGEP has filed many patent oppositions, including successful challenges to patents on islatravir, sofosbuvir/velpatasvir, and remdesivir.